apremilast / Generic mfg. - LARVOL DELTA

Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics. (PubMed, Curr Issues Mol Biol) - "Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options...This review provides a comprehensive analysis of key agents including Janus kinase (JAK) inhibitors (upadacitinib, abrocitinib, baricitinib, ruxolitinib, delgocitinib), phosphodiesterase 4 (PDE4) inhibitors (crisaborole, difamilast, roflumilast, apremilast), as well as STAT6 degraders (KT621, NX3911), aryl hydrocarbon receptor modulators, histamine H4 receptor antagonists (adriforant, izuforant), and sphingosine-1-phosphate receptor modulators (etrasimod, BMS-986166). We summarize their mechanisms of action, pharmacological profiles, and pivotal clinical trial data, emphasizing their potential to address unmet therapeutic needs. Finally, we discuss safety concerns, long-term tolerability, and future directions for integrating small molecule..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • STAT6

Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index. (PubMed, Reumatol Clin (Engl Ed)) - "Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA."

Clinical • Journal • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment (clinicaltrials.gov) - P3 | N=693 | Active, not recruiting | Sponsor: Takeda | Trial completion date: Apr 2026 ➔ Nov 2025 | Trial primary completion date: Aug 2025 ➔ Jan 2025

Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

Single-Center Cross-Sectional Analysis of Patients with RA, SpA, and PsA: Data from the Prescription Database. (PubMed, J Pers Med) - "For RA, 34.2% of patients were difficult to treat (D2T) (98 pt), 54.8% (157 pt) were in monotherapy (tocilizumab-sarilumab-upadacitinib-filgotinib). Abatacept was the most prescribed treatment in RF and ACPA-positive patients and in those with ILD. The anti-IL-17A secukinumab was prescribed in 12% of SpA, of which 71% had enthesitis and dactylitis (14 pt). Ixekizumab was prescribed in 10.4% of PsA patients over 65 years with previous CV events, enthesitis, and dactylitis (21 pt). Apremilast was present in 71% of PsA with previous cancer...The cross-sectional analysis of prescriptions in patients with RA, SpA, and PsA demonstrates how the ITABIO recommendations can guide towards the correct appropriateness of prescription. RA and especially D2T-RA remains the disease with the greatest therapeutic failures, with the highest percentage of monotherapy (anti-IL-6 and Jak-i) and of discontinuation of MTX."

Journal • Ankylosing Spondylitis • Cardiovascular • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Interstitial Lung Disease • Metabolic Disorders • Ocular Inflammation • Oncology • Ophthalmology • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Our review shows that, compared to placebo, the biologics infliximab, xeligekimab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis, with high-certainty evidence for bimekizumab and moderate-certainty evidence for infliximab, xeligekimab, ixekizumab, and risankizumab. This network meta-analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice. More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis)...."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Generalized Pustular Psoriasis as a Systemic Inflammatory Disease: Experience With 38 Japanese Cases Over 15 Years at a Single Institution. (PubMed, Cureus) - "Pustular psoriasis is a rare subtype of psoriasis, classified into two broad forms: generalized and localized. In the present study, we retrospectively analyzed 41 cases of pustular psoriasis over a 15-year period at a single institution. There were 38 cases of generalized and three cases of localized pustular psoriasis. Among the 38 patients with generalized pustular psoriasis (GPP), 15 (39.5%) had a prior history of psoriasis, while the remaining patients developed GPP de novo. Eighteen patients were former or current smokers, and arthritis was observed in 12 patients. Four patients, including one with Turner syndrome, developed GPP in childhood. Episodes of generalized pustulation occurred once in seven patients, once in three patients, twice in three patients, and three times in one patient. The triggers of pustulation were upper respiratory infection (n=2), pregnancy (n=2), withdrawal of methotrexate (n=1), and paradoxical..."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Crohn's disease • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Genetic Disorders • Heart Failure • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Renal Disease • Respiratory Diseases • Rheumatology • Turners Syndrome • S100A8 • S100A9

Apremilast Improves Patient-reported Pain Regardless of Sex and Age in Early Oligoarticular Psoriatic Arthritis: A Post-hoc Analysis From FOREMOST (EADV 2025) - No abstract available

Clinical • Retrospective data • Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy of Apremilast in Paediatric Patients With Plaque Psoriasis According to Disease Duration in the SPROUT Randomised Controlled Trial (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Pediatrics • Psoriasis

Targeted Impact: Apremilast Treatment Outcomes According to High-Impact Sites for Plaque Psoriasis with Limited Skin Involvement – A Post-Hoc Analysis from EMBRACE (EADV 2025) - No abstract available

Clinical • Retrospective data • Dermatology • Immunology • Psoriasis

Apremilast Reduces Epicardial Adipose Tissue in Psoriasis (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis

Characteristics of Quality-of-Life High Responders With Plaque Psoriasis and High-Impact Site Involvement Treated With Apremilast: A Post Hoc Analysis of the EMBRACE Trial (EADV 2025) - No abstract available

HEOR • Retrospective data • Dermatology • Immunology • Psoriasis

Apremilast Survival in Clinical Practice: Real-World Evidence from a Greek Dermatology Center (EADV 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology

Progression from oligoarticular to polyarticular psoriatic arthritis differs by sex, with consistent responses to apremilast observed across both sexes: Data from FOREMOST (EADV 2025) - No abstract available

Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Apremilast treatment is effective at treating both palms and soles in Japanese patients with moderate to severe palmoplantar pustulosis: Post-hoc analysis of a phase 3 study (EADV 2025) - No abstract available

Clinical • P3 data • Retrospective data • Immunology • Psoriasis

Apremilast as a Therapeutic Option for Chronic Cutaneous Lichen Planus with Concomitant Psoriasis: A Case Report (EADV 2025) - No abstract available

Case report • Clinical • Dermatology • Dermatopathology • Immunology • Lichen Planus • Psoriasis

emerging role of apremilast in hand dermatoses (EADV 2025) - No abstract available

Dermatology

Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review. (PubMed, Front Pharmacol) - "Thus, further large-scale studies and real-life trials are necessary to better elucidate its role in dermatology. The present narrative review provides an overview of apremilast as a novel therapeutic option for skin disorders, including a comprehensive look at its pharmacology, clinical efficacy, and safety profile, with the aim of enlightening clinicians on the broad applications and full potential of this small-molecule drug based on currently available evidence."

Journal • Review • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rare Diseases • Rheumatology • Seronegative Spondyloarthropathies

Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study. (PubMed, J Drugs Dermatol) - "Apremilast was safe and moderately efficacious for the treatment of CCCA, with patients showing statistically significant improvements in several investigator and patient-reported outcomes. Larger, placebo-controlled studies investigating therapies for CCCA are warranted. Adverse events (AEs) were consistent with the known safety profile of apremilast and may limit the use of this medication in some patients."

Journal • Alopecia • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Pain • Pruritus

Production and characterization of fermented solid derived from cocoa waste for lead adsorption in water. (PubMed, Environ Sci Pollut Res Int) - "To produce the adsorbent, the fungus Aspergillus niger ATCC 1004 was inoculated into cocoa pod husk bran...FS achieved a 90% adsorption efficiency for Pb2⁺, compared to 76% for NFS. Therefore, fermenting cocoa pod husks significantly enhances the material's adsorption capacity, making it a promising adsorbent for removing lead ions from aqueous solutions."

Journal

PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats (NACFC 2025) - No abstract available

Preclinical • Infectious Disease • Inflammation

PDE4 inhibitor apremilast ameliorates TNBS-induced irritable bowel syndrome in mice by activating the Nrf-2 signaling pathway in enteric glial cells. (PubMed, Acta Pharmacol Sin) - "These effects depended on the activation of the nuclear factor erythroid 2-related factor 2 (Nrf-2) signaling pathway, which was validated in Nrf-2 knockout EGCs. These results suggest that inhibition of PDE4 by apremilast suppresses EGCs activation by activating the Nrf-2 signaling pathway, leading to decreased expression of pain mediators and inflammatory factors while ameliorating oxidative stress, ultimately alleviating IBS."

Journal • Preclinical • Gastrointestinal Disorder • Immunology • Pain • IFNG • TNFA

Treatment of moderate-to-severe psoriasis with first-line tumor necrosis factor inhibitors or apremilast is associated with fast and frequent treatment failures and greater healthcare resource utilization and costs [WITHDRAWN] (EADV 2025) - No abstract available

Clinical • HEOR • Dermatology • Immunology • Oncology • Psoriasis

Ustekinumab in the Treatment of Intestinal Manifestations of Behcet's Disease (ACG 2025) - "Biopsy of the lesion showed vulvular neutrophilic dermatoses which prompted initiation of prednisone and cyclosporine. The patient developed hypertension on this regimen and transitioned to azathioprine...She was switched to adalimumab, colchicine and hydroxychloroquine by rheumatology...The medical team attempted methotrexate to prevent chronic glucocorticoid use, but the patient self-discontinued this medication due to gastrointestinal intolerance...She remains in clinical remission on Ustekinumab, apremilast, and sulfasalazine. A group of patients with intestinal BD experience disease refractory to mainstay therapy...This case demonstrates that, in patients with intestinal BD, Ustekinumab appears to be a potentially effective treatment. It represents a promising treatment option for intestinal BD, and further studies are needed."

Cardiovascular • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Rare Diseases • Rheumatology

A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis. (PubMed, Clin Rheumatol) - "Accumulating research, albeit of differing robustness, suggests that bimekizumab could potentially offer superior efficacy compared to other therapies in attaining both the PASI 75 and PASI 90 response thresholds in psoriasis treatment. Tildrakizumab appears to have achieved the highest proportion of participants reaching a static Physician's Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1). Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies. Key Points • The NMA of 66 RCTs reveals that infliximab, bimekizumab, and tildrakizumab are superior in achieving PASI 75, PASI 90, and sPGA 0/1, respectively, in moderate-to-severe plaque psoriasis, underscoring their therapeutic significance. • Deucravacitinib, an oral TYK2 inhibitor, outperforms placebo and apremilast in efficacy for moderate-to-severe plaque..."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • TYK2

Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study (ACG 2025) - "Here, we report Week 24(W24) results. APEX enrolled biologic naïve adults with active PsA (≥3 tender & ≥3 swollen joints; C-reactive protein ≥0.3mg/dL) and ≥2 erosive joints on radiographs of hands and feet despite previous non-biologic DMARDs, apremilast, or NSAIDs. BL characteristics were similar across groups. Mean duration of PsA(7.3yrs), PsA-modified vdH-S total(27.0) and erosion(13.5) scores, and tender(20.7) and swollen(11.9) joint counts indicated established, highly active joint disease. Primary and major secondary endpoints were met."

Clinical • P3 data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP